Compared to very few PSMA-targeted chemotherapeutics, many PSMA-targeting radionuclides have been developed and entered into clinical trials for the treatment of metastatic prostate cancer [34,35,36,68,69,70]. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.